A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Status Enrolling by invitation

Clinical Trial Summary

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05774756
Study type	Interventional
Source	Rhythm Pharmaceuticals, Inc.
Contact
Status	Enrolling by invitation
Phase	Phase 3
Start date	April 26, 2023
Completion date	April 16, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02849743` - Intranasal Oxytocin in Hypothalamic Obesity	Phase 2
Recruiting	`NCT06217848` - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study	Early Phase 1
Withdrawn	`NCT05147415` - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)	Phase 2
Completed	`NCT00892073` - Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy	Phase 2
Not yet recruiting	`NCT06299891` - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity	Phase 2
Recruiting	`NCT06239116` - A Study of RM-718 in Healthy Subjects and in Patients With HO	Phase 1
Completed	`NCT02664441` - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity	Phase 3
Completed	`NCT04725240` - Open-Label Study of Setmelanotide in Hypothalamic Obesity	Phase 2
Completed	`NCT03673813` - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Not yet recruiting	`NCT06046443` - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity	Phase 2
Withdrawn	`NCT03708913` - Neuromodulation for Hypothalamic Obesity	N/A
Completed	`NCT01061775` - Effects of Exenatide on Hypothalamic Obesity	Phase 1/Phase 2
Completed	`NCT02860923` - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy	Phase 3
Completed	`NCT00171613` - A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients	Phase 4
Recruiting	`NCT01783717` - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage	N/A
Completed	`NCT05319301` - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)	N/A